Study Finds Obstacles to Search for Opioid Substitute
Inflation Reduction Act price controls on the category of drugs that includes most non-opioid pain relievers reduce return on investment, disincentivize research funding BOSTON – By reducing return on investment for the category of drugs that includes most potential non-opioid pain relievers, the Inflation Reduction Act (IRA) creates a major disincentive to the development of therapies to combat the opioid epidemic that is ravaging the United States, according to a new study published by Pioneer Institute. The problem is exacerbated by the fact that pain medication research already has a higher attrition rate than research in other therapies. A 2023 Biotechnology Industry Organization (BIO) study found that pain projects have only a o.7 percent probability of gaining FDA approval, compared […]